The upcoming presentation on June 5 is a binary event. If data details confirm strong mortality benefit, EDSA could rally significantly. Monitor for full data release and key metrics (e.g., mortality rate reduction, safety profile). Given the small cap and prior volatility, position sizing should account for potential 50%+ moves.
Price Chart
Executive Summary
Edesa Biotech announced an oral presentation of Phase 3 data for paridiprubart in acute kidney injury at the ERA Congress (June 5, 2026). The company claims a statistically significant reduction in mortality, a high-mortality condition with no approved therapies. The event could serve as a major catalyst given Edesa's $75M market cap and positive prior data.
Key Facts
- Oral presentation of Phase 3 data for paridiprubart in AKI at ERA Congress on June 5, 2026
- Company states 'consistent, statistically significant reduction in mortality' in AKI patients
- No approved pharmacological therapies currently exist for AKI
- Edesa is a clinical-stage biopharma with $75M market cap
Financial Impact
Not specified
Risk Factors
- Presentation may reveal underwhelming data or fail to impress investors
- No specific numerical data provided in the press release – actual results could differ from management's characterization
- Stock has high volatility and may be susceptible to profit-taking after recent gains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297637 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $2.59 | awaiting T+20 | — | $2.63 (+1.54%) |
Oct 15, 2026 12d ago | 8-K | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Oct 15, 2026 12d ago | Press Release | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Aug 19, 2026 9w ago | Press Release | $4.76 $4.14 | ▲ +13.03% | ▲ +13.03% | $2.63 (+44.75%) |
Jul 14, 2026 15w ago | EFFECT | $6.74 $5.52 | ▲ +18.10% | ▲ +20.59% | $2.63 (+60.98%) |
Jul 2, 2026 16w ago | S-3 | $7.50 $5.25 | ▼ −30.00% | ▼ −29.59% | $2.63 (−64.93%) |
Jun 5, 2026 20w ago | 8-K | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
Jun 5, 2026 20w ago | Press Release | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
May 29, 2026 21w ago | 8-K | $6.69 $8.13 | ▲ +21.52% | ▲ +22.82% | $2.63 (−60.69%) |
May 19, 2026 23w ago | Press Release | $11.95 $6.88 | ▼ −42.43% | ▼ −43.41% | $2.63 (−77.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers